# DE NOVO PHARMACEUTICALS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/de-novo-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, UK
- Website: www.denovopharma.com
- Total disclosed funding: $23M
- Latest round: Series B (Jul 26, 2001)
- Investors on record: 11

## About

De Novo Pharmaceuticals is a biotechnology firm focused on developing innovative drug treatments through advanced molecular design and synthetic chemistry, aiming to address significant unmet medical needs.Founded in 1999 and headquartered in Cambridge, UK, De Novo Pharmaceuticals specializes in the design and development of novel therapeutic agents. In July 2001, the company raised EUR 27.3 million in a Series B funding round led by Merlin Biosciences Fund Ltd and included investors like Avlar BioVentures and Roche. This funding marked a pivotal moment in the company's growth trajectory.De Novo Pharmaceuticals focuses on developing a range of pharmaceutical products aimed at creating novel drug candidates through innovative synthetic and molecular design techniques. The company's expertise lies in structure-based drug design, providing tailored solutions for pharmaceutical needs.In 2022, De Novo Pharmaceuticals recorded a revenue of EUR 0 with an EBITDA also reported at EUR 0 for the year 2023.De Novo Pharmaceuticals plans to utilize the recent EUR 27.3 million raised from its Series B funding to support the launch of new drug candidates under development, with specific timelines for market entry yet to be announced. The company is targeting expansion into new European and North American markets in the coming years to broaden its reach and enhance its impact within the pharmaceutical industry.

## Funding rounds

- Series B, Jul 26, 2001, $23M — Avlar BioVentures, Quester Capital Management, Wellcome Trust, Cambridge Gateway Fund, Life Science Venture Partners, Prelude Ventures, FNI Venture Capital, Roche, Incyte Corporation, Merlin Biosciences Fund Ltd, CRIL

## Investors

- Avlar BioVentures (https://capitalatlas.ai/funds/avlar-bioventures) — Series B
- Quester Capital Management (https://capitalatlas.ai/funds/quester-capital-management) — Series B
- Wellcome Trust — Series B
- Cambridge Gateway Fund (https://capitalatlas.ai/funds/cambridge-gateway-fund) — Series B
- Life Science Venture Partners — Series B
- Prelude Ventures — Series B
- FNI Venture Capital — Series B
- Roche — Series B
- Incyte Corporation — Series B
- Merlin Biosciences Fund Ltd — Series B
- CRIL (https://capitalatlas.ai/funds/cril) — Series B